20 Oct 2016 --- Resveratrol, a component of red wine and grapes, may help control inflammation induced by a bacterial pathogen that is linked to upper respiratory tract inflammatory diseases, according to a new study published in Scientific Reports.
“It has been shown that resveratrol can suppress inflammation, but how it regulates inflammation still remains largely unknown,” said Jian-Dong Li, a senior author of the study, director of the Institute for Biomedical Sciences at Georgia State, and a Georgia Research Alliance Eminent Scholar.
“We found that resveratrol suppresses a major bacterial pathogen causing otitis media and chronic obstructive pulmonary diseases (COPD) by up-regulating or increasing the production of a negative regulator called MyD88 short.”
Resveratrol belongs to a group of compounds called polyphenols that are thought to act like antioxidants and protect the body against damage. It has long been considered a therapeutic agent for various diseases, including inflammatory diseases.
In the study, resveratrol was effective against inflammation caused by nontypeable Haemophilus influenzae (NTHi), a major respiratory pathogen.
This study found for the first time that resveratrol decreases NTHi-induced expression of pro-inflammatory mediators in airway epithelial cells and in the lungs of mice by enhancing MyD88 short, a negative regulator of inflammatory signaling pathways.
MyD88 short is considered a “brake pedal protein” because it can tightly control inflammation induced by this respiratory pathogen. It could be a critical target with significant therapeutic potential for suppressing inflammation associated with chronic airway disease.
The researchers also found that resveratrol has anti-inflammatory effects after NTHi infection, which demonstrates its therapeutic potential.
To contact our editorial team please email us at
10 Aug 2018 –
Salutivia has been appointed as the UK ...
08 Aug 2018 –
Raisio is targeting renewed growth for its ...
06 Aug 2018 –
The European Food Safety Authority (EFSA) Panel ...
21 Jun 2018 –
General Mills' venture arm, 301 Inc., is ...
11 May 2018 –
US researchers examining how to manipulate gut ...